Jacobio Pharma announced clinical results of its novel KRAS G12C inhibitor glecirasib monotherapy and in combination therapy with cetuximab to treat KRAS G12C mutant advanced CRC in Second JCA- AACR Precision Medicine International Conference.
Jacobio Pharma announced clinical results of its novel KRAS G12C inhibitor glecirasib monotherapy and in combination therapy with cetuximab to treat KRAS G12C mutant advanced CRC in Second JCA- AACR Precision Medicine International Conference.